Adlai Nortye (NASDAQ:ANL) Director Ping Ji Sells 5,000 Shares of Stock

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Director Ping Ji sold 5,000 shares of the company’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $16.63, for a total value of $83,150.00. Following the sale, the director owned 131,667 shares of the company’s stock, valued at approximately $2,189,622.21. This trade represents a 3.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Adlai Nortye Trading Up 0.5%

Shares of ANL opened at $15.83 on Friday. The company has a current ratio of 9.55, a quick ratio of 0.65 and a debt-to-equity ratio of 0.04. Adlai Nortye Ltd. Sponsored ADR has a one year low of $0.88 and a one year high of $17.25. The company’s fifty day moving average price is $13.98 and its 200 day moving average price is $12.00.

Institutional Investors Weigh In On Adlai Nortye

Several large investors have recently modified their holdings of ANL. Braidwell LP bought a new position in shares of Adlai Nortye during the 2nd quarter worth approximately $9,145,000. Boone Capital Management LLC bought a new stake in Adlai Nortye in the second quarter valued at $2,971,000. Seven Fleet Capital Management LP acquired a new position in Adlai Nortye during the second quarter worth $1,302,000. Affinity Asset Advisors LLC acquired a new position in Adlai Nortye during the first quarter worth $1,140,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Adlai Nortye during the first quarter valued at $816,000. 35.21% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ANL shares. Cantor Fitzgerald initiated coverage on shares of Adlai Nortye in a research note on Monday, June 22nd. They issued an “overweight” rating for the company. Wall Street Zen lowered Adlai Nortye from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Jefferies Financial Group began coverage on Adlai Nortye in a research report on Thursday, September 10th. They set a “buy” rating and a $31.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Finally, Loop Capital set a $49.00 price target on shares of Adlai Nortye in a research note on Tuesday, September 8th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Adlai Nortye currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

About Adlai Nortye

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company’s research and development activities center on oncology and immuno-oncology, with the goal of addressing unmet needs in the treatment of solid tumors.

Adlai Nortye’s lead candidate is buparlisib, also known as AN2025, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor being developed for oncology indications, including head and neck cancer.